The “Stepping Stone” Approach to Getting Longevity Drugs to Market - proto.life
proto.life · 1,933 words · saved by 1 readers
Getting geroprotective drugs to market for specific disease applications is the first step in eventually making them available for healthier aging.
The “Stepping Stone” Approach to Getting Longevity Drugs to Market Getting geroprotective drugs to market for specific disease applications is the first step in eventually making them available for healthier aging. By Jason Socrates Bardi Illustrations by Nathalie Lees Share Share on Twitter Share on Facebook Go Deeper Business Drugs Longevity Medicine The silver tsunami is coming. By 2050, the number of people in the world over the age 60 will double, making up a fifth of the world’s population. Two-thirds of them will live in low-income and middle-income countries but health systems and econ
related reading
- What the Aging Field Needs - Celine Haliouacelinehh.com
- Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
- Longevity FAQ - Laura Demingldeming.com
- What we wish we knew entering the aging fieldlibrariesforthefuture.bio
- Anti-Aging: State of the Art — LessWronglesswrong.com
- My Aging Thesis — Celine Haliouacelinehh.com
- Cure all diseasesworksinprogress.news
- The longevity tech market map: 64 startups racing to defy deathcbinsights.com
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Nintil - The Longevity FAQnintil.com
- Why is progress in biology so slow?sam-rodriques.com
- A primer on the current state of longevity researchowlposting.com